NovaBay Pharmaceuticals (NBY) EBIAT (2016 - 2025)
Historic EBIAT for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.
- NovaBay Pharmaceuticals' EBIAT rose 2810.14% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.1 million, marking a year-over-year increase of 5220.7%. This contributed to the annual value of -$7.2 million for FY2024, which is 2507.26% up from last year.
- Latest data reveals that NovaBay Pharmaceuticals reported EBIAT of -$1.3 million as of Q3 2025, which was up 2810.14% from -$371000.0 recorded in Q4 2024.
- In the past 5 years, NovaBay Pharmaceuticals' EBIAT registered a high of -$111000.0 during Q1 2022, and its lowest value of -$8.2 million during Q4 2022.
- For the 5-year period, NovaBay Pharmaceuticals' EBIAT averaged around -$2.0 million, with its median value being -$1.8 million (2023).
- Data for NovaBay Pharmaceuticals' EBIAT shows a peak YoY increase of 9405.85% (in 2022) and a maximum YoY decrease of 509367.09% (in 2022) over the last 5 years.
- Over the past 5 years, NovaBay Pharmaceuticals' EBIAT (Quarter) stood at -$158000.0 in 2021, then crashed by 5093.67% to -$8.2 million in 2022, then soared by 49.94% to -$4.1 million in 2023, then skyrocketed by 90.97% to -$371000.0 in 2024, then crashed by 259.3% to -$1.3 million in 2025.
- Its last three reported values are -$1.3 million in Q3 2025, -$371000.0 for Q4 2024, and -$1.9 million during Q3 2024.